Prothena (NASDAQ:PRTA) used its fourth-quarter and full-year 2025 results call to highlight partner-driven clinical momentum, updates from its wholly owned preclinical portfolio, and a sharper cash ...
I am pleased to report another strong quarter for Radian, rounding out an outstanding year, both in terms of our financial performance and the beginning of an exciting strategic transformation of our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results